For the quarter ended December 2025, Danaher (DHR) reported revenue of $6.84 billion, up 4.6% over the same period last year. EPS came in at $2.23, compared to $2.14 in the year-ago quarter.
The reported revenue represents a surprise of +0.64% over the Zacks Consensus Estimate of $6.79 billion. With the consensus EPS estimate being $2.22, the EPS surprise was +0.68%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Total Growth - Organic sales (Core): 2.5% versus 1.8% estimated by six analysts on average.
- Total sales- Biotechnology: $2.03 billion versus the five-analyst average estimate of $2.02 billion. The reported number represents a year-over-year change of +8.8%.
- Total sales- Diagnostics: $2.72 billion versus $2.7 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +3.2% change.
- Total sales- Life Sciences: $2.09 billion compared to the $2.06 billion average estimate based on five analysts. The reported number represents a change of +2.6% year over year.
- Operating profit- Biotechnology: $540 million versus $535.78 million estimated by three analysts on average.
- Operating profit- Other: $-87 million versus $-88.23 million estimated by three analysts on average.
- Operating profit- Diagnostics: $713 million versus $690.13 million estimated by three analysts on average.
- Operating profit- Life Sciences: $336 million compared to the $258.78 million average estimate based on three analysts.
View all Key Company Metrics for Danaher here>>>
Shares of Danaher have returned +2.2% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>Danaher Corporation (DHR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
